Previous Research

12. Arnatt, C. K.; Zhang, Y. Current status of bivalent ligands targeting chemokine receptor dimers: design and function. Current Topics in Medicinal Chemistry 2014, in press. [Link]
11. Arnatt, C. K.; Adams, J. L.; Zhang, Z.; Haney, K. M.; Guo, Li, Zhang, Y. Design, synthesis, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents. Bioorganic & Medicinal Chemistry Letters 2014, 24, 2319-2323. [Link]
10. Zaidi, S. A.; Arnatt, C. K.; He, H.; Selley, D. E.; Mosier, P. E.; Kellogg, G. E.; Zhang, Y. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: Application of the ‘message-address’ concept in development of mu opioid receptor selective antagonists. Bioorganic & Medicinal Chemistry, 2013, 21, 6405-6413. [Link]
9. Arnatt, C. K.; Zaidi, S. A.; Zhang, Z.; Li, G.; Richardson, A. C.; Ware, J. L.; Zhang, Y. Design, synthesis, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents. European Journal of Medicinal Chemistry, 2013 69, 647-658. [Link]
8. El-Hage, N.; Dever, S. M.; Podhaizer, E. M.; Arnatt, C. K.; Zhang, Y.; Hauser, K. F. A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-µ-opioid receptor interactions between human astroglia and microglia. AIDS 2013, 27, 2181-2190. [Link]
7. Arnatt, C. K.; Zhang, Y. G protein-coupled estrogen receptor (GPER) agonist dual binding mode analyses toward understanding of its activation mechanism: a comparative homology modeling approach. Molecular Informatics 2013, 32, 647-658. [Link]
6. Yuan, Y.; Arnatt, C. K.; El-Hage, N.; Dever, S.; Jacob, J.; Selley, D.; Hauser, K.; Zhang, Y. A bivalent ligand targeting the putative mu opioid receptor and chemokine receptor CCR5 heterodimers: binding affinity versus functional activities. Med. Chem. Comm. 2013, 4, 847-851. [Link]
5. Zhang, F.; Arnatt, C. K.; Haney, K. M.; Fang, H. C.; Bajacan, J. E.; Richardson, A. C.; Ware, J. L.; Zhang, Y. Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents. European Journal of Medicinal Chemistry 2012, 55, 395-408. [Link]
4. Zhang, Y.; Arnatt, C. K.; Zhang, F.; Wang, J.; Haney, K. M.; Fang, X. The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents. Bioorganic & Medicinal Chemistry Letters 2012, 22, 5093-5097. [Link]
3. Yuan, Y.; Arnatt, C. K.; Li, G.; Haney, K. M.; Ding, D.; Jacob, J. C.; Selley, D. E.; Zhang, Y. Design and synthesis of a ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5. Organic & Biomolecular Chemistry 2012, 10, 2633-2646. [Link]
2. Arnatt, C. K.; Zhang, Y. Facile synthesis of 2,3,5,6-tetrabromo-4-methyl-nitrocyclohexa- 2,5-dien-1-one, a mild nitration reagent. Tetrahedron Letters 2012, 53, 1592-1594. [Link]
1. Haney, K. M.; Zhang, F.; Arnatt, C. K.; Yuan, Y.; Li, G.; Ware, J. L.; Gerwirtz, D. A.; Zhang, Y. The natural product CCR5 antagonist anibamine and its analogs as antiprostate cancer agents. Bioorganic & Medicinal Chemistry Letters 2011, 21, 5159-63. [Link]